𝗙𝗶𝗿𝘀𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗧𝗿𝗲𝗮𝘁𝗲𝗱 𝗶𝗻 𝗚𝗿𝗼𝘂𝗻𝗱-𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗠𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝘁 𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗦𝘁𝘂𝗱𝘆 Read more ▶️ https://lnkd.in/eipyB-eQ 🔬 Jean-Chris Marine of VIB-KU Leuven Center for Cancer Biology, and Oliver Bechter of UZ Leuven, in collaboration with Presage Biosciences, Inc., have treated the first patient in an innovative phase I pilot study. This study tests a new approach 👉 injecting up to 7 different drugs directly into the tumor while also giving the patient a standard anti-PD1 therapy. Using Presage’s CIVO® microinjection device, researchers can see how the tumor reacts to different treatments at the same time. 💡The goal? To better understand how melanoma responds to treatment and improve future therapies. #CancerResearch #Melanoma #Immunotherapy #PrecisionMedicine #Oncology #Innovation
Our long standing collaboration has now spun out the first interventional clinical trial. Eagerly awaiting first data, there is obviously more to come!
Join me at the frontier of Spatial Biology
2wCongrats Chris, exciting times ahead.